1. Home
  2. ACRS vs ALCO Comparison

ACRS vs ALCO Comparison

Compare ACRS & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • ALCO
  • Stock Information
  • Founded
  • ACRS 2012
  • ALCO 1960
  • Country
  • ACRS United States
  • ALCO United States
  • Employees
  • ACRS N/A
  • ALCO N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • ALCO
  • Sector
  • ACRS Health Care
  • ALCO
  • Exchange
  • ACRS Nasdaq
  • ALCO Nasdaq
  • Market Cap
  • ACRS 230.8M
  • ALCO 267.7M
  • IPO Year
  • ACRS 2015
  • ALCO N/A
  • Fundamental
  • Price
  • ACRS $2.85
  • ALCO $34.17
  • Analyst Decision
  • ACRS Strong Buy
  • ALCO
  • Analyst Count
  • ACRS 5
  • ALCO 0
  • Target Price
  • ACRS $9.75
  • ALCO N/A
  • AVG Volume (30 Days)
  • ACRS 1.4M
  • ALCO 22.3K
  • Earning Date
  • ACRS 11-06-2025
  • ALCO 11-24-2025
  • Dividend Yield
  • ACRS N/A
  • ALCO 0.58%
  • EPS Growth
  • ACRS N/A
  • ALCO N/A
  • EPS
  • ACRS N/A
  • ALCO N/A
  • Revenue
  • ACRS $15,742,000.00
  • ALCO $44,066,000.00
  • Revenue This Year
  • ACRS N/A
  • ALCO N/A
  • Revenue Next Year
  • ACRS N/A
  • ALCO N/A
  • P/E Ratio
  • ACRS N/A
  • ALCO N/A
  • Revenue Growth
  • ACRS N/A
  • ALCO N/A
  • 52 Week Low
  • ACRS $1.05
  • ALCO $24.76
  • 52 Week High
  • ACRS $4.24
  • ALCO $35.90
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 67.71
  • ALCO 60.86
  • Support Level
  • ACRS $2.34
  • ALCO $31.42
  • Resistance Level
  • ACRS $2.57
  • ALCO $32.25
  • Average True Range (ATR)
  • ACRS 0.22
  • ALCO 0.81
  • MACD
  • ACRS 0.03
  • ALCO 0.12
  • Stochastic Oscillator
  • ACRS 96.18
  • ALCO 96.78

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.

Share on Social Networks: